In some cases where testing was indicated but cost was an issue for the patient, we recommended that they proceed solely with testing for a single gene (e.g., CYP2C19) instead of testing on the GatorPGx panel or forgoing testing altogether, based on the likelihood of the patient having an “actionable” result for that gene (e.g., patient with uncontrolled depression was referred to clinic because they failed escitalopram, a CYP2C19-guided SSRI) and cheaper cost. Here, CYP2C19 is linked to depressive symptom measurement.